Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Corporate Management Decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A (BoNT-A) treatment naïve participants.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Facial treatment with incobotulinumtoxinA in treatment naïve participants |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| IncobotulinumtoxinA | Drug | IncobotulinumtoxinA injections for aesthetic indications. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of FACE-Q Patient-Perceived Age Visual Analogue Scale mean change | Explore the effectiveness of the incobotulinumtoxinA injections in treatment naïve participants for facial cosmetic procedures during up to 3 years continuous treatment exposure, as measured by assessment of FACE-Q Patient-Perceived Age Visual Analogue Scale mean change from first treatment visit to the 4-to-6 weeks timepoint. | Up to 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of FACE-Q Satisfaction with Decision Scale mean change | Explore the effectiveness of the incobotulinumtoxinA injections in treatment naïve participants for facial cosmetic procedures during up to 3 years continuous treatment exposure, as measured by assessment of FACE-Q Satisfaction with Decision Scale mean change from first treatment visit to the 4-to-6 weeks timepoint. | Up to 3 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Male and female participants, 18 years of age or older, seeking treatment with incobotulinumtoxinA for UFL in the North American, Latin American, European, and Asia-Pacific regions.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| SkinDC | Arlington | Virginia | 22209 | United States |
Not provided
| ID | Term |
|---|---|
| C545476 | incobotulinumtoxinA |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided